Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Group 1 - The company, Hefei Lifan Pharmaceutical Co., Ltd., has received the drug registration certificate for Mesalazine enteric-coated tablets from the National Medical Products Administration [1] - Mesalazine is a non-steroidal anti-inflammatory drug that significantly inhibits inflammation in the intestinal mucosa, suitable for treating acute episodes of ulcerative colitis and maintaining remission, as well as treating acute episodes of Crohn's disease [1] - The approval of Mesalazine enteric-coated tablets will enhance the company's product pipeline and market competitiveness, with four other domestic companies holding the same specification drug approval and three others holding different specifications [1]

Core Points - Recently, the company received the drug registration certificate for Mesalazine enteric-coated tablets from the National Medical Products Administration [2] Company Summary - The approval of the drug registration certificate is a significant milestone for the company, indicating progress in its product development and regulatory compliance [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration certificate of Mesalazine enteric-coated tablets, indicating a significant advancement in its product offerings [1] Company Summary - The approved product, Mesalazine, is a non-steroidal anti-inflammatory drug that inhibits the synthesis of prostaglandins and the formation of inflammatory mediators such as leukotrienes, thereby significantly suppressing inflammation in the intestinal mucosa [1] - Mesalazine enteric-coated tablets are indicated for the treatment of acute exacerbations of ulcerative colitis and for maintenance therapy to prevent recurrence, as well as for the treatment of acute exacerbations of Crohn's disease [1] - The original developer of Mesalazine is the German company Fuchs Pharma GmbH [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of Mesalazine enteric-coated tablets, indicating a significant advancement in its product offerings [1]. Group 1: Product Approval - The approval pertains to Mesalazine, a non-steroidal anti-inflammatory drug that inhibits the synthesis of prostaglandins and the formation of inflammatory mediators such as leukotrienes, thereby significantly suppressing inflammation in the intestinal mucosa [1]. - Mesalazine enteric-coated tablets are indicated for the treatment of acute exacerbations of ulcerative colitis and for maintenance therapy to prevent recurrence, as well as for the treatment of acute exacerbations of Crohn's disease [1]. - The original developer of Mesalazine is the German company, Ferring Pharmaceuticals [1].

证券代码：003020 证券简称：立方制药 公告编号：2025-050 合肥立方制药股份有限公司 关于取得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、药品注册批准情况 | 药品名称： | 美沙拉秦肠溶片 | 申请事项： | 药品注册(境内生产) | | --- | --- | --- | --- | | 剂型： | 片剂 | 注册分类： | 化学药品4类 | | 规格： | 0.5g | 药品有效期： | 18个月 | | 药品批准文号： | 国药准字H20254987 | 药品批准文号 有效期： | 至2030年07月28日 | | 上市许可持有人： | | 合肥立方制药股份有限公司 | | | 生产企业： | | 合肥立方制药股份有限公司 | | 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签 及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可 生产销售。 二、药品其他相关情况 美沙拉秦是一种非甾体抗炎药，可以抑制 ...

Core Viewpoint - The approval of Mesalazine enteric-coated tablets by the National Medical Products Administration enhances the company's product pipeline and market competitiveness [1] Company Summary - The company, Lifan Pharmaceutical (003020.SZ), has received the drug registration certificate for Mesalazine enteric-coated tablets, which are indicated for the treatment of acute exacerbations of ulcerative colitis and maintenance therapy to prevent recurrence, as well as for acute exacerbations of Crohn's disease [1] - As of the announcement date, in addition to imported products and the company, there are four domestic enterprises holding the same specification drug approval, and three others holding approvals for different specifications [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）收到国家药品监督管理局下发的盐 酸丙美卡因《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、《化学原料药上市申请批准通知书》主要内容 申请事项：境内生产化学原料药上市申请 化学原料药名称：盐酸丙美卡因 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：003020 证券简称：立方制药 公告编号：2025-049 合肥立方制药股份有限公司 关于收到原料药上市申请批准通知书的公告 二、盐酸丙美卡因的相关情况 盐酸丙美卡因是一种强效酯类表面麻醉剂，其制剂盐酸丙美卡因滴眼液临床上主要用于眼科表面麻醉 等，是一种快速作用的局部麻醉药。截至本公告日，盐酸丙美卡因原料药暂无进口原料药登记备案，除 公司外，国产原料药目前有五家企业登记备案，登记状态均为"A"（已批准在上市制剂使用的原料）。 三、对公司的影响及风险提示 公司盐酸丙美卡因滴眼液已于2025年2月获得《药品注册证书》（公告编号：2025-007）。此次原料药 上市申请获得批准，将进一 ...

天眼查商业履历信息显示，合肥立方制药股份有限公司，成立于2002年，位于合肥市，是一家以从事医 药制造业为主的企业。企业注册资本19018.2182万人民币，实缴资本6600万人民币。公司法定代表人为 季俊虬。 金融界消息 截至2025年7月29日收盘，立方制药（003020）报收于27.24元，下跌1.48%，换手率 15.63%，成交量21.53万手，成交金额5.95亿元。 资金流向方面，今日主力资金净流出1523.10万元，占比成交额2.56%。其中，超大单净流出879.68万 元、占成交额1.48%，大单净流出643.41万元、占成交额1.08%，中单净流出流入2006.48万元、占成交 额3.37%，小单净流出483.39万元、占成交额0.81%。 立方制药最新一期业绩显示，截至2025一季报，公司营业总收入3.60亿元、同比增长7.98%，归属净利 润3825.03万元，同比增长25.94%，扣非净利润3160.17万元，同比增长11.28%，流动比率2.142、速动比 率1.723、资产负债率24.82%。 通过天眼查大数据分析，合肥立方制药股份有限公司共对外投资了11家企业，参与招投标项目50 ...